川芎嗪联合阿托伐他汀治疗冠心病心绞痛患者的效果OA
Effect of Ligustrazine Combined with Atorvastatin on Patients with Angina Pectoris of Coronary Heart Disease
目的:探讨川芎嗪联合阿托伐他汀治疗冠心病心绞痛的效果.方法:选取 2020 年 12 月—2022 年 12 月贵州省人民医院邮电医院收治的 86 例冠心病心绞痛患者作为研究对象,按照随机数表法分为两组,各 43 例.对照组给予阿托伐他汀钙片口服治疗,观察组在对照组基础上给予磷酸川芎嗪注射液治疗,两组均连续治 10 d.比较两组治疗前后心绞痛发作情况、心功能指标、脂代谢指标、生活质量变化情况,并记录两组不良反应发生情况.结果:治疗前,两组心绞痛发作持续时间、心绞痛发作频率、视觉模拟评分法(VAS)、全血高切黏度、血浆黏度、全血低切黏度、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、总胆固醇(TC)、脑钠肽(BNP)、C反应蛋白(CRP)及健康状况调查问卷(SF-36)评分比较,差异无统计学意义(P>0.05);治疗 10 d后,观察组心绞痛发作持续时间短于对照组,心绞痛发作频率、VAS评分、全血高切黏度、血浆黏度、全血低切黏度、LDL-C、TG、TC、BNP、CRP均低于对照组,HDL-C及SF-36 中各项评分均高于对照组,差异有统计学意义(P<0.05).两组不良反应总发生率比较,差异无统计学意义(P>0.05).结论:川芎嗪联合阿托伐他汀治疗冠心病心绞痛的效果显著,能够有效改善患者心绞痛情况,改善血液流变学,调节脂代谢水平,提高生活质量,且安全性高.
Objective:To investigate the effect of Ligustrazine combined with Atorvastatin on angina pectoris of coronary heart disease.Method:A total of 86 patients with angina pectoris of coronary heart disease admitted to the Post and Telecommunications Hospital of Guizhou Provincial People's Hospital from December 2020 to December 2022 were selected as the study objects and divided into two groups according to random number table method,with 43 cases in each group.The control group was treated with Atorvastatin Calcium Tablets orally,and the observation group was treated with Ligustrazine Phosphate Injection on the basis of the control group.Both groups were treated continuously for 10 d.Angina pectoris attack,cardiac function index,lipid metabolism index and quality of life before and after treatment were compared between the two groups,and adverse reactions between the two groups were recorded.Result:Before treatment,there were no significant differences in duration of angina pectoris attacks,frequency of angina pectoris attacks,visual analogue scale(VAS)score,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),triglyceride(TG),total cholesterol(TC),brain natriuretic peptide(BNP),C-reactive protein(CRP),the MOS item short from health survey(SF-36)score between the two groups(P>0.05).After 10 d of treatment,duration of angina pectoris attacks in the observation group was shorter than that in the control group,frequency of angina pectoris attacks,VAS score,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,LDL-C,TG,TC,BNP and CRP in the observation group were lower than those in the control group,and HDL-C and SF-36 scores in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Ligustrazine combined with Atorvastatin has a significant effect in the treatment of angina pectoris of coronary heart disease,which can effectively improve the condition of angina pectoris of patients,improve hemorheology,regulate lipid metabolism,improve quality of life,and have high safety.
袁敏;高海军;查远琼;吴琴;娄国梁
贵州省人民医院邮电医院 贵州 贵阳 550001
冠心病心绞痛川芎嗪阿托伐他汀脂代谢心绞痛发作血液流变学
Angina pectoris of coronary heart diseaseLigustrazineAtorvastatinLipid metabolismAngina attackBlood rheology
《中外医学研究》 2024 (017)
17-20 / 4
评论